Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

This pilot study investigated the safety and efficacy of a personalized neoantigen peptide-pulsed autologous DC vaccine (Neo-DCVac) in treating advanced lung cancer. Twelve heavily treated metastatic lung cancer patients received a median of 5 doses of Neo-DCVac, each containing 12-30 peptide-based neoantigens selected via whole-exome and RNA sequencing. The vaccine was well-tolerated with only grade 1-2 adverse events. The objective response rate was 25%, disease control rate 75%, median progression-free survival 5.5 months, and median overall survival 7.9 months. The study suggests Neo-DCVac as a feasible and potentially effective treatment option for advanced lung cancer.

Zhenyu Ding, Qing Li, Rui Zhang, Li Xie, Yang Shu, Song Gao, Peipei Wang, Xiaoqing Su, Yun Qin, Yuelan Wang, Juemin Fang, Zhongzheng Zhu, Xuyang Xia, Guochao Wei, Hui Wang, Hong Qian, Xianling Guo, Zhibo Gao, Yu Wang, Yuquan Wei, Qing Xu, Heng Xu, Li Yang